ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. ROME was launched in April 2020 and was incubated at GV, in collaboration with ARCH Venture Partners and Partners Innovation Fund. ROME is based in Cambridge, Mass. For more information, please visit www.rometx.com.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $50M
Founded date: 2020
Investors 3
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | S32 | s32.com |
| - | GV | gv.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.04.2020 | Series A | $50M | GV |
Mentions in press and media 9
| Date | Title | Description |
| 13.10.2023 | ROME Therapeutics Lands $149M Series B | BOSTON, MA, ROME Therapeutics, a biotechnology company, announced the completion of an oversubscribed $72 million Series B extension financing. >> Click here for more funding data on ROME Therapeutics >> To export ROME Thera... |
| 10.01.2022 | New Year, New Fund, New Opportunities in Bio + Health | 2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both upstarts and tradit... |
| 14.09.2021 | Rome Therapeutics Raises $77M Series B | Biotech startup, Rome Therapeutics, Raises $77M Series B |
| 14.09.2021 | ROME Therapeutics : Secures $77 Million in Series B Financing to Advance Repeatome-derived Pipeline for Cancer and Autoimmune Diseases and Expand Repeatomics Platform | ROME Therapeutics, a biotechnology company harnessing the power of the repeatome for drug development, today announced the completion of a $77 million Series B financing led by new investor Section 32. In addition, new investors Sanofi Vent... |
| 28.04.2020 | Rome Therapeutics Raises $50M in Series A Financing | Rome Therapeutics, a Cambridge, Mass.-based biotechnology company leveraging repeatome for drug development, launched with $50m in Series A funding. Backers included GV, Arch Venture Partners and Partners Innovation Fund. Led by CEO, Presid... |
| 27.04.2020 | ROME Therapeutics Launches with $50M Series A | CAMBRIDGE, MA, ROME Therapeutics launched today with $50M in Series A funding from GV, ARCH Venture Partners and Partners Innovation Fund. >> Click here for more funding data on ROME Therapeutics >> To export ROME Therapeuti... |
| 27.04.2020 | Rome Therapeutics Launches with $50M to Tackle Small-Molecule Drugs for Cancer | - |
| 27.04.2020 | GV joins $50 million round in Rome Therapeutics to research ‘junk DNA’ for cancer therapies | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! Rome Therapeutics, a biotechnology startup that’s... |
| 27.04.2020 | GV joins $50 million round in Rome Therapeutics to research ‘junk DNA’ for cancer therapies | Rome Therapeutics, a biotechnology startup that’s using machine learning (ML) to explore the human genome and develop new treatments for cancer and autoimmune diseases, has launched out of stealth today with $50 million in series A funding ... |